Stoke Therapeutics, Inc. (STOK) — closed signal from January 28, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on April 28, 2026.
Predicted vs. what happened
What happened
Reached its target in 26 days.
The thesis — published January 28, 2026
Stoke is a small biotech that recently showed real progress: they are expanding facilities and gave clearer timelines for late-stage tests. That helped investors stay interested even though the stock fell. Trading is light and prices are still recovering, so this is a short-term, careful trade. If selling calms, the stock could bounce strongly within a few months.
Primary drivers
- Facility growth shows they are preparing to scale drug development and future sales
- Clearer late-stage test timing keeps attention on the main program
- Stock fell too far and could bounce if selling eases
- Adds healthcare exposure to reduce tech-heavy portfolio risk
How it played out
STOK: target reached in 26 days
Lyra published STOK on 2026-01-28 at 30.06 as a short-term healthcare signal. The thesis expected 20% growth. It pointed to facility growth, clearer late-stage test timing, a stock that had fallen too far, and the chance of a bounce if selling eased.
Inside the window from 2026-01-28 to 2026-04-28, STOK reached the 36.07 target in 26 days. It peaked at 40.22 on 2026-03-10, with a 33.8% gain at the peak. It ended the window at 33.33. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.